Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.
$599
Posted in: Basal Insulin, Glucagon, Insulin Delivery, Other Nov 10 | 2021MannKind and Xeris Biopharma Q3 ’21 Earnings UpdatesPurchase Blast
$599
Posted in: Glucose Monitoring, Other, SGLT2i Nov 09 | 2021Bayer and Senseonics Q3 '21 Earnings Updates; Abbott and ADA Launch Community Initiative; Provention Bio Launches #Type1TestedPledge Campaign; Beyond Type 1 Receives $750,000 GrantPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, DPP-IVi, GLP-1RA, Other Nov 08 | 2021November 8-11 CHMP Agenda; Kerendia+SGLT2i Reduce Risk of Composite CV Outcome; Viatris Q3 ’21 Earnings UpdatePurchase Blast
$599
Posted in: GLP-1RA, Glucagon, Glucose Monitoring, Insulin Delivery, Other, SGLT2i Nov 05 | 2021GSK’s Daprodustat Ph3 Data Positive But Not Entirely Clean; BI/Lilly’s Jardiance Demonstrates Consistent Cardio-Renal Benefits in HF; Novo Announces Positive Ph3b STEP 5 Trial Results; CytoDyn Reports Positive Preliminary Data from Ph2 Leronlimab Trial; Roche and Sanofi Mallya Collaboration; Intuity Medical’s Automatic BGM Available in US; Zealand and DEKA Collaboration for Continuous Infusion PumpPurchase Blast
$599
Posted in: Basal Insulin, Insulin Delivery, Other Nov 04 | 2021Viatris’s Semglee Gains Preferred Status on Prime Therapeutics’s National Formularies; Zealand’s First Patient Dosed with ZP8396 in Ph1 Trial for Obesity; Insulet, Lannett, Ionis, Provention Bio, BD, and Regeneron Q3 ‘21 Earnings UpdatesPurchase Blast
$599
Posted in: Bolus Insulin, Glucose Monitoring, Insulin Delivery, Other, SGLT2i Nov 03 | 2021Lexicon, Tandem, Amarin, Intercept, and Amgen Q3 '21 Earnings UpdatesPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, Other Nov 03 | 2021Novo Nordisk Q3 '21 Earnings UpdatePurchase Blast
$599
Posted in: GLP-1RA, Other, SGLT2i Nov 02 | 2021Ionis Initiates New Ph3 Study in Hypertriglyceridemia; Real-World Evidence Study of PDT BT-001 for T2DM; Metacrine Announces MET409 Topline Results; Esperion and Pfizer Q3 ’21 Earnings UpdatesPurchase Blast
$599
Posted in: Dual/triple agonist, Glucose Monitoring, Other Nov 01 | 2021Zealand Announces Presentation of Preclinical and Clinical Data on ZP8396 and BI 456906; BING Innovations Launches DigiVibe; Dario Signs Remote Patient Monitoring Services Contracts; National Diabetes Awareness Month ActivitiesPurchase Blast
$599
Posted in: Basal Insulin, GLP-1RA, Other Oct 29 | 2021Novo Raises 2021 Guidance; Novo’s “Bigger Than Me” Anti-Obesity Awareness Campaign; Biocon’s Form 483 Observations Revealed; Novel Human Neo-Islet Technology PublishedPurchase Blast
$599
Posted in: Basal Insulin, DPP-IVi, GLP-1RA + Basal, Other, SGLT2i Oct 28 | 2021Novartis’s Entresto Marketing Under DOJ Investigation?; Inventiva’s Ph2a Lanifibranor + Empa Trial (LEGEND); Merck and Sanofi Q3 ’21 Earnings Updates; Roche and Zur Rose Group CollaborationPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, Other Oct 27 | 2021Sinocare and EoFlow Diabetes Tech Collaboration; Provention Announces Positive Interim Results for Ph1 PROVENT Trial; Dario Partners with Virgin Pulse; Teva and Adocia Q3 ’21 Earnings UpdatesPurchase Blast
$599
Posted in: Basal Insulin, Dual/triple agonist, Other, SGLT2i Oct 26 | 2021Lilly and Novartis Q3 '21 Earnings UpdatesPurchase Blast
$599
Posted in: Glucose Monitoring, Other Oct 25 | 2021Apple Watch 8 Reportedly Set to Include BGM; Lifescan Launches OneTouch Solutions; Xeris and Merck Collaboration; Dario Partners with New Employer Group; Tidepool Period Project Receives Financial SupportPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Other Oct 22 | 2021Metacrine Discontinues NASH Program; Ikenna Ogbaa Joins GSK to Lead Daprodustat Medical Team; Biocon CY Q3 '21 (FY Q2 '22) Earnings Update; Integrity Applications Hires New President and COOPurchase Blast
$599
Posted in: Basal Insulin, Glucose Monitoring, Other Oct 20 | 2021Viatris' Semglee Preferred on Express Scripts NPF; DreaMed’s Advisor Pro Launched in Leading Children’s Hospital; MiniMed 780G & Guardian 3 TIR In Pediatrics Comparable to Adults; Abbott and Roche Q3 '21 Earnings Updates; vTv Therapeutics Hires New President and CEO; Adhera Adds Target Indications for MLR-1023Purchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, Glucose Monitoring, Other Oct 19 | 2021Lilly’s Ph3 Tirzepatide SURPASS-4 Results Published in Lancet; FDA Pre-Submission for rt-Glucose Salivary Test; Ultrahuman Hires Chief Business Officer; J&J Q3 ‘21 Earnings UpdatePurchase Blast
$599
Posted in: Insulin Delivery, Other Oct 18 | 2021Medtronic to Acquire Triple Jump?; Esperion to Reduce Workforce by 40%; Diamyd’s Ph3 T1DM Vaccine Trial Initiated; Vertex Announces Positive Results From Ph1/2 VX-880 TrialPurchase BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.
